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Idiopathic pulmonary
ﬁbrosisAbstract Background: Idiopathic pulmonary ﬁbrosis (IPF) is a chronic ﬁbrotic lung disease with
a median survival rate ranging from 2 to 3 years from diagnosis. Recent data have illustrated the
role of gastro-esophageal reﬂux (GER) in the pathogenesis and potential management of IPF
patients. Although it is recognized that GER is increased among IPF patients, its prevalence and
characteristics had been poorly deﬁned.
Patients and methods: Forty patients were recruited; 20 with a diagnosis of IPF and the other, 20
with interstitial lung disease other than IPF (non IPF patients). All patients underwent pulmonary
high-resolution computed tomography (HRCT) scan and impedance-pH monitoring while off anti-
secretory therapy. The presence of pulmonary ﬁbrosis was assessed using validated HRCT scores.
Reﬂux features included distal esophageal acid exposure, number of acid/weakly acidic reﬂux epi-
sodes and their proximal migration.
Results: Seventeen (85%) patients out of 20 with IPF had an abnormal distal acid exposure,
compared with 7 (35%) out of 20 non IPF patients (p= 0.003). Percentage total acid exposure time
(AET) with pH < 4 was signiﬁcantly higher in IPF compared with non IPF patients (median
(range) 10.1 (5.1–16.3) versus 3 (1.2–8.3), respectively; p< 0.0001). In IPF patients the total (both
acid and weakly acidic) numbers of reﬂux episodes [80 (45–99)], acid reﬂux [46 (25–57)] and weakly
acidic reﬂux [35 (20–45)] were signiﬁcantly higher than those of non IPF patients (45 (29–70), 28
(18–40) and 19 (10–30), respectively; p< 0.0001). Also, more reﬂux episodes reached the proximal
esophagus [54 (28–69)] in IPF patients than non-IPF patients [18 (8–32); p< 0.0001]. In IPF
patients there was a signiﬁcant positive correlation between degree of pulmonary ﬁbrosis (HRCT
score) and total number of reﬂux episodes in both the distal (r2 = 0.57, p= 0.008) and proximal
(r2 = 0.61, p= 0.004) esophagus. In contrast, in non IPF patients a non signiﬁcant correlation
was found between degree of pulmonary ﬁbrosis and total number of reﬂux episodes in both the
distal (r2 = 0.17, p= 0.48) and proximal (r2 = 0.23, p= 0.34) esophagus.d.
506 S. Embarak et al.Conclusion: IPF patients have greater GER rate compared to non IPF ones. Not only acid
reﬂux, but also weakly acidic reﬂux is signiﬁcantly increased among IPF patients.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is deﬁned as a speciﬁc
form of chronic ﬁbrosing interstitial pneumonia limited to
the lung and associated with the histologic appearance of usual
interstitial pneumonia (UIP) on surgical (thoracoscopic or
open) lung biopsy [1]. No therapy has been clearly shown to
prolong survival [2]. Gastro-esophageal reﬂux (GER) disease
has been previously associated with a number of interstitial
lung diseases (ILDs) [3–7].
Recent investigations have demonstrated stabilization or
delay of pulmonary ﬁbrosis progression after medical or surgi-
cal treatment of GER [8–10]. In particular, Lee et al. [10]
showed that the use of GER medications is associated with
decreased radiologic ﬁbrosis and is an independent predictor
of longer survival time in patients with IPF. However, other
studies highlighted that lung injury is independent of acidity
and factors other than acid (i.e. foods, pepsin and bile acids)
may be involved in its pathogenesis [11,12]. In particular, Mer-
tens et al. [12] showed that exposure of bronchial epithelial
cells to gastric juice from patients on anti-secretory therapy
is able to induce high interleukin-8 production, the most rele-
vant cytokine for the acute-phase response of inﬂammation.
In IPF patients, GER has previously been assessed by
means of 24-h pHmetry that permits detection of acid reﬂux
only. The recent use of impedance–pH monitoring allows us
to detect both acid and weakly acidic GER and to assess the
extent of reﬂux into the proximal esophagus [13,14]. So, the
aim of this study was to further explore the association of
GER and pulmonary ﬁbrosis by assessing the prevalence of
all kinds of reﬂux in patients with IPF versus patients with
ILD other than IPF.Patients and methods
Patients
This study was carried out at Chest, Internal Medicine, Trop-
ical Medicine and Radiology Departments and Outpatient
Clinics, Zagazig University Hospitals during the period from
January 2012 through January 2014. It included 20 patients
with a deﬁnite diagnosis of IPF. The diagnosis of IPF was
based on the absence of an identiﬁable etiology for ILD and
a histopathological/radiological pattern of usual interstitial
pneumonia on surgical lung biopsy and high-resolution com-
puted tomography (HRCT) scans [1]. Another 20 consecutive
patients with ILD other than IPF, referred for outpatient clinic
follow up, were also enrolled for comparison. They were 4
patients with sarcoidosis, 8 patients with systemic lupus erythe-
matosus, 5 patients with mixed connective tissue disease and 3
patients with bronchiolitis obliterans organizing pneumonia,
who were diagnosed according to the characteristichistopathological ﬁndings on surgical lung biopsy or
appropriate autoimmune markers and clinical presentations
[15–18].
Methods
All patients were asked to discontinue any medication that
would inﬂuence esophageal motility (i.e. nitrates, calcium
antagonists, domperidone, benzodiazepines and metoclopra-
mide) and acid suppressive therapy P30 days before the start
of the study.
All studied patients were subjected to the following:
1. Thorough medical history.
2. Full clinical examination (general and local
examination).
3. Pulmonary investigations
Pulmonary involvement was systematically investigated
during the initial evaluation of IPF in all patients, by
chest radiography, HRCT scan of the lungs and pul-
monary function tests.
a. Pulmonary function tests:
Forced vital capacity (FVC) and forced expiratory
volume (FEV1) curves were measured using a com-
puterized pulmonary function device (Sensor Medics
2450, CA, USA). Pulmonary function was considered
abnormal if volumes were < 80% predicted values
[19].
b Pulmonary HRCT:
High resolution scanning of the lungs was performed
using standardized protocols to identify radiographic
abnormalities related to IPF [1]. HRCT scans were
evaluated by two experienced radiologists, indepen-
dently and in a random order without the knowledge
of the patients’ status. Any discrepancy in the assess-
ment was discussed further and a consensus was
reached. A semiquantitative analysis of the severity
of ﬁbrosis on HRCT was calculated by estimating
the percentage of the lung affected by ﬁbrosis (i.e.
reticular abnormality and/or honeycombing) to the
nearest 5% in three zones for each lung according
to Best et al. [20]. These numbers were averaged to
obtain a net radiologic ﬁbrosis score using a 4-point
scale (0 = no involvement, 1 = 1–25% involvement,
2 = 26–50% involvement, 3 = 51–75% involve-
ment, and 4 = 76–100% involvement) [21].4. Esophageal investigations
a. Manometry testing:Esophageal manometry was performed by means of
multichannel intraluminal impedance-esophageal
manometry according to Savarino and Tutuian [22].
Lower esophageal sphincter (LOS) pressure, upper
esophageal sphincter (UES) pressure, peak contraction
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sured. Manometric patterns were reported according
to international criteria [23].b. Impedance–pH monitoring:Studies were performed off proton pump inhibitor
treatment and according to Savarino et al. [24].GER episodes were classiﬁed as acid (pH < 4), weakly
acidic (pH 4–7) and weakly alkaline (pH > 7) following estab-
lished criteria [25].
Number and type of reﬂux episodes, acid exposure (reﬂux
time (min) and reﬂux percentage time) and proximal extent
(reﬂux reaching 15 cm above the LOS) were calculated [26].
Total distal esophageal acid exposure <4.2% over 24 h was
considered normal [27,28]. Number of reﬂux episodes <54 was
considered normal [29].
Statistical analysis
Statistical analysis was performed with Epi Info version 7
and the SPSS version 19 statistical software package1 Demographic and clinical data of all studied patients.
eter IPF (n= 20)
ean ± SD 66.1 ± 14.8
/F 11/9
t smokers, no (%) 10 (50%)
kg/m2 23 ± 6.5
nary symptomsa, no (%) 18 (90%)
, no (%) 8 (40%)
57 ± 20
54 ± 20
ageal symptomsb, no (%) 10 (50%)
medicationc, no (%) 8 (40%)
le; F: female; BMI: body mass index.
. cough and dyspnea; LTOT: long term oxygen therapy; FVC: forc
. heart burn and regurgitation; GER: gastro-esophageal reﬂux.
. proton pump inhibitor or H2 blocker.
2 Esophageal manometric data in all studied patients.
eter IPF (n=
basal LES pressure, mmHg 14.5 (4.5–
proximal contraction amplitude, mmHg 93.5 (45–1
distal contraction amplitude, mmHg 89.5 (15–2
metric hiatal hernia, no (%) 10 (50%)
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3 Esophageal 24-h impedance-pH data in all studied patient
eter IPF (n= 20)
acid exposure, no (%) 17 (85%)
al AET (with pH< 4) 10.1(5.1–16.3)
reﬂux episodes 80 (45–99)
eﬂux episodes (pH < 4) 46 (25–57)
y acidic reﬂux episodes (pH 4–7) 35 (20–45)
al reﬂux episodes 54 (28–69)
acid exposure time.(SPSS Inc., Chicago, IL, USA). Differences in proportions
were compared using the Chi-squared or Fisher’s exact test.
As reﬂux parameters were not normally distributed, results
are reported as median and range. Differences between
groups were assessed using Kruskal–Wallis and/or Mann–
Whitney tests. The correlation between the severity of
pulmonary ﬁbrosis and reﬂux parameters was calculated
using Spearman correlation. p-value < 0.05 was considered
signiﬁcant.Results
This study included 20 patients with a deﬁnite diagnosis of IPF
and 20 with pulmonary ﬁbrosis other than IPF (non-IPF).
Table 1 shows no statistically signiﬁcant differences between
studied groups as regards detailed demographic and clinical
characteristics.
Table 2 shows similar esophageal manometric parameters
between patients with IPF and non IPF patients without statis-
tically signiﬁcant differences.Non IPF ILD (n= 20) p-Value
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r esophageal sphincter; UES: upper esophageal sphincter.
s.
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Figure 1 Median values of esophageal total acid exposure time
(AET) in patients with idiopathic pulmonary ﬁbrosis (IPF)
(n= 20) and non IPF patients (n= 20).
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Figure 2 Number and type of gastro-esophageal reﬂux in
patients with IPF (n= 20) and non IPF patients (n= 20). Data
are presented as median values and range.
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Figure 3 Number of reﬂux episodes reaching the proximal
esophagus in patients with idiopathic pulmonary ﬁbrosis (IPF)
(n= 20) and non IPF patients. Data are presented as median
values and range.
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Figure 4 Correlation between degree of pulmonary ﬁbrosis
(HRCT score) and total number of reﬂux episodes in the distal
esophagus in patients with idiopathic pulmonary ﬁbrosis (IPF).
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Figure 5 Correlation between degree of pulmonary ﬁbrosis
(HRCT score) and total number of reﬂux episodes in the proximal
esophagus in patients with idiopathic pulmonary ﬁbrosis (IPF).
508 S. Embarak et al.Table 3 shows that 17 (85%) patients out of 20 with IPF
had an abnormal distal acid exposure, compared with 7
(35%) out of 20 non-IPF patients (p= 0.003). Percentage
total acid exposure time (AET) with pH< 4 was signiﬁcantly
higher in IPF compared with non-IPF patients (percentage
total AET 10.1 (5.1–16.3) versus 3 (1.2–8.3), for IPF versus
non-IPF patients, respectively; p< 0.0001) (Fig. 1). In IPF
patients the total (both acid and weakly acidic) numbers of
reﬂux episodes [80 (45–99)], acid reﬂux [46 (25–57)] and weakly
acidic reﬂux [35 (20–45)] were signiﬁcantly higher than those of
non IPF patients (45 (29–70), 28 (18–40) and 19 (10–30),
respectively; p< 0.0001) (Fig. 2). Also, more reﬂux episodes
reached the proximal esophagus [54 (28–69)] in IPF patients
than non-IPF patients [18 (8–32); p< 0.0001] (Fig. 3).
Figs. 4 and 5 show that in IPF patients there was a good
correlation between degree of pulmonary ﬁbrosis (HRCT
score) and total number of reﬂux episodes in both the distal
(r2 = 0.57, p= 0.008) and proximal (r2 = 0.61, p= 0.004)
esophagus. In contrast, as shown in Figs. 6 and 7 in non-
IPF patients a non signiﬁcant correlation was found between
(r 2 =0.17, p=0.48)
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Figure 6 Correlation between degree of pulmonary ﬁbrosis
(HRCT score) and total number of reﬂux episodes in the distal
esophagus in non IPF patients.
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Figure 7 Correlation between degree of pulmonary ﬁbrosis
(HRCT score) and total number of reﬂux episodes in the proximal
esophagus in non IPF patients.
Characteristics of gastro-esophageal reﬂux 509degree of pulmonary ﬁbrosis and total number of reﬂux
episodes in both the distal (r2 = 0.17, p= 0.48) and proximal
(r2 = 0.23, p= 0.34) esophagus (Fig. 8).Figure 8 HRCT showing reticular pattern, ﬁne ﬁbrotic strands, tDiscussion
Idiopathic pulmonary ﬁbrosis (IPF) is a chronic ﬁbrotic lung
disease with a median survival ranging from 2 to 3 years from
diagnosis [1]. Pulmonary ﬁbrosis can occur after repeated tra-
cheobronchial aspiration of small amounts of gastric contents
over long periods of time (i.e. chronic microaspiration) [30,31].
Moreover, recent investigations have demonstrated disease
stabilization or delay of disease progression after medical or
surgical treatment of GER [8–10]. Until recently, diagnosis
and therapy of GER have focused on gastric acid as the main
monitoring parameter and treatment target [26]. However,
recent studies highlighted that lung injury is independent of
acidity and factors other than acid (i.e. foods, pepsin and bile
acids) may be involved in its pathogenesis [12,13]. Although it
is recognized that GER is increased in IPF patients, its preva-
lence and characteristics have been poorly deﬁned. The recent
use of impedance-pH monitoring allows us to detect both acid
and weakly acidic GER and to assess the extent of reﬂux into
the proximal esophagus [13,14]. So, in the current work, we
investigated esophageal motility, acid and weakly acidic reﬂux
and proximal migration of reﬂuxate, as well as the correlation
between GER and lung ﬁbrosis in patients with IPF. We com-
pared the results with those obtained from patients with ILD
other than IPF.
Table 1 shows that IPF patients had a mean age of
66.1 ± 14.8 years. This is in accordance with data from many
other studies which illustrated that patients with IPF are often
middle aged, usually between 40 and 70 years of age. Approx-
imately two-thirds of patients with IPF are over the age of
60 years at the time of presentation, with a mean age at diag-
nosis of 66 years [32–37]. Moreover, the incidence of the dis-
ease increases with older age [38,39].
In case-control studies, cigarette smoking has been identi-
ﬁed as a potential risk factor with the odds ratio (OR) from
various regions of the world ranging from 1.6 to 2.9 for the
development of IPF in ever-smokers [40–42]. Our study
showed that IPF patients tended to have a higher smoking his-
tory compared with non-IPF patients, but without statistical
signiﬁcance.
Results of this study showed a higher frequency of GER
episodes (both acid and weakly acidic) and reﬂux episodes
reaching the proximal esophagus in patients with IPF when
compared with non IPF patients (Table 3 and Figs. 2 and 3),
despite similar esophageal manometric parameters (Table 2).raction bronchiectasis, and minimal ground glass attenuation.
510 S. Embarak et al.Also, a good correlation between the degree of pulmonary
ﬁbrosis and the severity of GER was found in patients with
IPF. These ﬁndings, with the non signiﬁcant correlation
between the degree of pulmonary ﬁbrosis and the severity of
GER in non IPF patients, suggest that patients with IPF have
more severe GER, potentially leading to more extensive lung
damage and ﬁbrosis progression. The aforementioned data
are consistent with the results obtained by Savarino et al. [26].
The mechanisms determining IPF are not clear. Current
concepts implicate epithelial–ﬁbroblast interactions as a result
of repeated insults to the lung parenchyma by an unknown
noxious stimulus. This prolonged stimulus would determine
the development of pulmonary ﬁbrosis over a long period of
time [1]. Recent studies have suggested chronic microaspira-
tion of gastric contents into the lungs as the trigger mechanism
able to induce pulmonary parenchymal lesions, thus leading to
the hypothesis that GER therapy could in part improve symp-
toms and pulmonary function test parameters [4–10]. This pos-
sibility has been recently conﬁrmed, by Lee et al. [10], who
observed that the use of GER medication was associated with
lower HRCT ﬁbrosis scores and was an independent predictor
of longer survival time in 96 out of 204 IPF patients. However,
all the above mentioned studies have been performed by means
of traditional pH-metry, which limited these investigations to
measuring only acid reﬂux without any information about
other chemical types (i.e. weakly acidic reﬂux), number of
reﬂux episodes, or the risk of proximal esophageal migration
of the reﬂuxate. Using combined impedance–pH monitoring,
IPF patients were observed to have a very severe degree of
overall reﬂux disease, compared to non IPF patients [26].
Moreover, the present study showed that IPF patients had
higher acid and weakly acidic reﬂux episodes in both the distal
and proximal esophagus, thus favoring the risk of microaspira-
tion into the lungs compared to non-IPF patients. Finding an
increased number of weakly acidic reﬂux episodes is of a great
importance, since this represents a possible explanation of why
medical acid suppression alone might fail in preventing reﬂux
and reﬂux-associated progression of ILD. Moreover, this ﬁnd-
ing supports the data from the study of Lee et al. [10], who
reported that IPF patients who underwent Nissen fundoplica-
tion in order to reduce both acid and weakly acidic GER had
an additional survival beneﬁt.
The good correlation we found between the degree of pul-
monary ﬁbrosis (HRCT score) and the number of both distal
and proximal reﬂux episodes in IPF patients (Figs. 4 and 5)
reinforces the potential role of GER in the development and/
or progression of pulmonary ﬁbrosis. But, the non signiﬁcant
correlation which was observed between the degree of pulmon-
ary ﬁbrosis and the number of both distal and proximal reﬂux
episodes in non IPF patients (Figs. 6 and 7) argues against the
hypothesis that abnormal GER in IPF subjects is the result of
the underlying ﬁbrosis of the lungs but has the potential to rep-
resent a factor unrelated to pulmonary stiffness [26].
Despite most (85%) of IPF patients in the present study
had abnormal GER (Table 3), only 50% (10 out of 20) com-
plained of GER symptoms (Table 1), this ﬁnding is in accor-
dance with previous studies [6,26,43]. Therefore, abnormal
acid or weakly acidic GER had been often clinically silent.
These results support the idea that all IPF patients with or
without apparent reﬂux symptoms should be carefully evalu-
ated and, eventually, should undergo esophageal impedance–
pH to detect asymptomatic GER [26].In conclusion, IPF patients have greater GER compared to
non IPF ones. Acid reﬂux is predominant, but also weakly
acidic reﬂux is increased among IPF patients. Abnormal
GER should be searched for and properly treated to prevent
microaspiration of gastric contents and its probable effects
on the natural history of lung ﬁbrosis in patients with IPF.
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